Cagrilintide/semaglutide, marketed as CagriSema, is a combination of
cagrilintide, a
dual amylin and calcitonin receptor agonist, and
semaglutide, a
GLP-1 agonist. It is injected once weekly and is being tested in
type 2 diabetes and
obesity. Preliminary trial results found a greater weight loss compared to either medication alone.
HbA1c was significantly improved compared to cagrilintide alone and non-significantly better than semaglutide alone.[1][2] In a Phase II trial, weight loss averaged -15.6 percent after 32 weeks, making CagriSema comparable in efficacy to
tirzepatide.[3][4] A future trial sponsored by Novo Nordisk is comparing tirzepatide and CagriSema head-to-head.[5] As of 2023, CagriSema is in a
Phase III trial.[6]